Our ResearchInflammatory Breast Cancer (IBC) is the most aggressive subtype of breast cancer with a low overall 5-year survival rate of ~30-60%. The poor prognosis for patients with IBC emphasizes the need to better understand the molecular signature of this disease. To this date, the molecular signature associated with IBC is not completely characterized. This leads to a lack of effective targeted therapeutics, especially for those patients that account for the 20-40% of triple-negative (TNBC) IBC cases. Our work, focuses on studying the activation of non‐genomic signaling pathways involved in the acquisition of pro-oncogenic phenotypes in triple-negative IBC cells.
|
Breast cancer symptoms; Health.com
|
Meet Dr. PetersonPrincipal Investigator"Dream big, set goals, take action."
-Dr. Peterson
|
Ongoing Projects |
Current Graduate Research Projects
|
The potential role of ERα36 in the estrogen signaling in Triple Negative -Inflammatory Breast Cancer |
Phytoestrogen coumestrol as an anticancer therapy against Triple-Negative Inflammatory Breast Cancer |
Mapping genomic translocations in Inflammatory Breast Cancer
|
Want to know more?
Discover our current undergraduate research projects. |
Science Needs You
Want to be part of our team and hear the latest updates of our research?
Stay up to date with our latest news and events
|
Stay connected through our social media
|
Get in touch
with us |
Peterson's Breast Cancer Research Lab
|
Department of Biology at University of Puerto Rico, Río Piedras Campus
|